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ABSTRACT 
 
 
Objective: 
The objective of this systematic review is to determine whether or not “Does N-acetylcysteine 
supplementation alleviate compulsive behavior in adults with impulse control disorders?” 
 
Study Design:  
Review of three English primary studies published between 2007 and 2009. 
 
Data Sources:  
One double-blind RCT, one open label trial followed by double-blind RCT, one case study. 
Studies were found using PubMed, Cochrane Systematic Reviews, OVID and Ebsco databases. 
 
Outcomes Measured:  
Primary outcomes measured include severity of trichotillomania symptoms measured by MGH-
HPS, reduction of pathological gambling symptoms measured by YBOCS-PG, and reduction of 
compulsive grooming urges measured by patient reports. 
 
Results: 
In Grant, Odlaug et al.’s study, 44% of subjects assigned to NAC had a 50% or greater reduction 
on the MGH-HPS compared to 0% of those assigned to placebo. In Grant, Kim et al.’s study, 
69.6% of subjects were responders on the PG-YBOCS at the end of the open-label NAC phase. 
At the end of the double-blind phase of the same trial, 83.3% of subjects assigned to NAC still 
met responder criteria, compared to 28.6% of subjects assigned to placebo. In Odlaug et al.’s 
study, 3 out of 5 subjects treated with NAC reported cessation of compulsive behaviors within 3-
5 months on 1800-2400 mg/day NAC.  
 
Conclusions:  
Evidence is inconclusive regarding the use of NAC in the treatment of impulse control disorders. 
Its use appears promising, but long term research in larger populations is indicated. Tailored 
treatment may be warranted based on the severity and type of impulse control disorder, the 
presence of co-morbid psychiatric disease, and individual treatment responses. Further insight 
into long-term effects of NAC is indicated before its widespread use in the clinical setting.  
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Introduction 
 Impulse control disorders (ICD’s) are relatively common psychiatric disorders for which 
the primary etiology is unknown.1 They are characterized by the irresistible impulse to engage in 
behaviors that are harmful or destructive to oneself or others.2 The DSM-IV currently recognizes 
the following ICD’s: pathological gambling (PG), kleptomania, trichotillomania (TTM), 
intermittent explosive disorder, and pyromania. Pathological skin picking (PSP), compulsive 
sexual behavior and compulsive buying are classified as Impulse Control Disorders Not 
Otherwise Specified.2 Consequences of ICD’s include impaired social and occupational 
functioning, decreased quality of life, financial loss and legal consequences.3, 4 This review is 
limited to the discussion of PG, TTM, and pathological grooming disorders including PSP. 
 In the US, the estimated lifetime prevalence of PG and TTM is 0.4-1.6% and 0.5-3.9%, 
respectively.2 Lifetime prevalence of PSP has been estimated to be 0.2-1.4% in the general 
population,2 2% of dermatology patients, and 3.8% of college students.5  Costs incurred for PSP 
and TTM include physicians’ and hospital fees, medication, psychotherapy, and cosmetic 
products and procedures to hide scarring and bald spots.6 Total costs for PG including health care 
expenses are estimated to be $5 billion annually.7 Estimated total health care costs and amount of 
annual health care visits for ICD’s are not available at this time.  
ICD’s are relatively common, yet their nature and treatment are poorly understood by 
health care providers.3 At this time there are no FDA-approved drugs for treatment of ICD’s.2 
Current methods of treatment include opioid antagonists, mood stabilizers, anti-depressants,8 
cognitive behavioral therapy (CBT),2 and support groups such as Gamblers Anonymous1 or Hair 
Pullers Anonymous. Individuals with TTM may benefit from topical steroids, hydroxyzine 
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hydrochloride or hypnosis.1 Treatments being used are not effective for all patients and more 
options are needed to optimize patient care.3, 4  
Animal studies have led to the hypothesis that the pathophysiology of behavioral 
addictions involves glutamate and dopamine actions in the nucleus accumbens.4  The reduction of 
compulsive behavior has been associated with restoration of extracellular glutamate 
concentration in the nucleus accumbens.3 N-acetylcysteine (NAC) is a hepatoprotective 
antioxidant believed to increase extracellular glutamate levels.4 In animal models, NAC has 
successfully penetrated the blood–brain barrier9 and reduced compulsive and reward-seeking 
behavior in rats with cocaine addiction.4 The question of whether the glutamatergic modulator 
NAC can have the same effect in humans has prompted various studies on the subject. 
NAC has been used for decades in the treatment of paracetamol overdose and more 
recently as a mucolytic and in the treatment of HIV.9 NAC has also shown some benefit in 
treating COPD and contrast-induced nephropathy.9 NAC may be effective as a relatively cheap 
non-prescription treatment for individuals with ICD’s. Treatment with NAC may be relevant to 
psychiatry based on its mechanism of action in non-specific pathways common to various 
psychopathologies.9 Alterations of oxidative stress, dysregulation of glutamate, and 
inflammatory pathways have been elucidated in psychiatric disease.9 NAC’s potential effect on 
these pathways makes it a source of continued interest. Furthermore, NAC’s limited adverse 
event profile may make it a good alternative to other pharmaceutical agents.4 This paper attempts 
to determine the efficacy of NAC as a treatment option for individuals with ICD’s.  
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Objective 
The objective of this systematic review is to determine whether or not “Does N-
acetylcysteine supplementation alleviate compulsive behavior in adults with impulse control 
disorders?” 
Methods 
  Studies reviewed include one case study, one double-blind RCT, and one open label trial 
followed by a double-blind RCT. All three studies analyze the effects of N-acetylcysteine in 
individuals over the age of 18 with a DSM-IV diagnosis of an impulse control disorder.3,4,5 
  The intervention applied in each study is NAC in doses between 600-2400 mg/day.3,4,5 
Subjects of the Grant, Kim et al. and Grant, Odlaug et al. studies were compared to an 
experimental group receiving an identical placebo for 12 weeks and 6 weeks, respectively.3,4 
Results from these two studies were obtained from clinical questionnaires. 3,4 Subjects in the 
Odlaug et al. study were not evaluated against a comparison group and results were obtained 
from patient reports. 5 Subjects in the Odlaug et al. study were treated for several months.5 
  The author searched for articles using PubMed, Cochrane Systematic Reviews, OVID 
and Ebsco using the keywords “N-acetylcysteine,” “trichotillomania,” “pathological gambling,” 
“glutamate,” and “impulse control disorders.”All articles were published in English in peer- 
reviewed journals. The inclusion criteria were RCT’s or case studies published after 1996 of 
adults aged 18 or older with an ICD. Articles were selected based on validity of the clinical 
trials, relevance to the author’s clinical hypothesis, and the inclusion of POEM’s. Studies of 
individuals under the age of 18 were excluded. Grant, Odlaug et al.’s study included CER, EER, 
a p-value of <.001 and a 95% confidence interval(CI).3 Grant, Kim et al.’s study included CER, 
EER, and a p-value of <.001.4 Studies were further evaluated by the author for RRR, ARR, and 
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NNT.  Odlaug et al.’s study did not include statistical values. Table 1 provides demographic 
information and specific characteristics of the studies included in this review.  
Table 1: Demographics and Characteristics of Included Studies 
Study Type #Pts Age  
(yrs.) 
Inclusion Criteria Exclusion Criteria W/D Interventions 
Grant, 
Odlaug 
et al. 
(2009) 
Double-
blind 
RCT 
50 18-59  Men and women 
aged 18-65 with a 
primary DSM-IV 
diagnosis of 
trichotillomania. 
Women required a 
negative pregnancy 
test result and the use 
of a medically 
acceptable 
contraceptive 
throughout the study  
History of seizures, unstable 
medical illness, bipolar 
disease, dementia, 
schizophrenia or psychotic 
disorder; abnormalities on 
physical exam/lab tests at 
screening; MI within 6 mos., 
substance abuse/dependence 
within 3 mos.; Current 
pregnancy/lactation; Lack of 
contraception in women of 
childbearing age; Reported 
suicidal thoughts; Previous 
NAC treatment; Asthma  
6 NAC 1200 mg/day 
x6 wks  increased 
to 2400 mg/d for 
remaining 6 weeks 
unless clinical 
improvement 
occurred at lower 
dose 
Grant, 
Kim et 
al.(2007) 
Open 
Label 
Trial 
 
 
 
 
 
 
 
 
 
 
 
 
27  21-
65  
Men and women 
aged 18-75 with a 
primary DSM-IV 
diagnosis of PG; 
Score of 15 or 
greater on PG-
YBOCS; Subjects 
required to have 
gambled within a 
week prior to 
enrollment ;Women 
required a negative 
pregnancy test result 
and the use of 
medically acceptable 
contraceptive 
throughout the study 
 
Gambling not meeting DSM-
IV criteria for PG; Current 
pregnancy/lactation; Lack of 
contraception in women of 
childbearing age; History of 
seizures, unstable medical 
illness, bipolar disease, 
dementia, schizophrenia, 
psychotic disorder; 
abnormalities on physical 
exam at screening; MI within 6 
mos., substance 
abuse/dependence within 3 
mos.; Previous NAC 
treatment; Positive urine drug 
screen test; psychotherapy or 
behavior therapy initiated 
within 3 mos. of study  
4 NAC 600 mg/d x2 
wks, increased to 
1200 mg/day x2 
wks, increased 
to1800 mg/d for 
remainder of study 
unless clinical 
improvement 
occurred at lower 
dose  
 
Subjects who 
responded to open-
label NAC  
randomized to dose 
at which they 
completed open-
label phase or 
identical placebo 
Followed 
by 
Double-
Blind 
RCT 
16 3 
Odlaug 
et 
al.(2007) 
Case 
Study 
5 28-52 Adults with 
pathological 
grooming behaviors 
N/A 2 N-acetylcysteine 
600-2400 mg/d 
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Outcomes Measured 
   Outcomes measured include the efficacy and tolerability of NAC in adults with TTM 
and in adults with PG, severity of TTM symptoms, reduction of PG symptoms, reduction of 
compulsive grooming behaviors, reduction of anxiety and depression, psychosocial function, and 
quality of life.3,4,5 Each of these outcomes qualifies as patient oriented evidence that matters. 
  The primary outcome measured in Grant, Odlaug et al.’s study was severity of TTM 
symptoms, measured by the Massachusetts General Hospital Hair Pulling Scale (MGH-HPS).3 
This is a 7-item scale that rates hair pulling urges and the associated behaviors and emotions.3 
Total scores range from 0-28.3 Secondary outcome measures in this study were measured by the 
Psychiatric Institute Trichotillomania Scale (PITS), Hamilton Anxiety Rating Scale (HAM-A), 
Hamilton Depression Rating Scale (HAM-D), Sheehan Disability Scale (SDS), Clinical Global 
Impression-Improvement and Severity Scales (CGI), and Quality of Life Inventory (QOLI).3 
This review is limited to results from MGH-HPS. 
 The primary outcome measured for the subjects of the Grant, Kim et al. study was 
reduction of PG symptoms, measured by The Yale Brown Obsessive Compulsive Scale 
Modified for Pathological Gambling (PG-YBOCS).4 This is a reliable 10-item clinician-
administered scale rating gambling symptoms from the past 7 days. 4 Total scores range from 0-
40.4 Secondary measures were assessed using the Gambling Symptom Assessment Scale (G-
SAS), CGI, SDS, HAM-A, HAM-D, and QOLI.4 This review is limited to results from the PG-
YBOCS. 
  The primary outcomes measured in Odlaug et al. were the reduction of compulsive 
grooming behaviors and associated urges.5 Specific behaviors included nail biting, hair pulling 
and skin picking, measured by reports from subjects.5 
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Results: 
Table 2: Key Values from Trials Being Reviewed in This Paper 
 P value CER EER RRR ARR NNT 
Grant, Odlaug et al. (2009) <.001 0 44% undefined 0.44 2 patients 
Grant, Kim et al. (2007) <.001 28.6% 83.3% 1.9 0.547 2 patients 
Oudlaug et al. (2007) N/A N/A N/A N/A N/A N/A 
 
The Grant, Odlaug et al. study involved a 12-week double-blind, placebo-controlled trial. 
Fifty subjects with trichotillomania were randomized to 12 weeks of double-blind NAC or 
placebo. Results were presented as dichotomous data analyzed with the last observation carried 
forward in the intention-to-treat (ITT) population. Primary and secondary measures were 
examined using ANOVA. Twenty two out of 25 subjects (88%) assigned to NAC and 22 out of 
25 subjects (88%) assigned to placebo completed the trial. Those who did not were either non-
compliant with the medication or could not complete the study due to unrelated health reasons.3 
 Subjects were seen every 3 weeks for 12 weeks. For the first 6 weeks subjects were given 
1200 mg/day NAC or identical placebo. NAC or placebo was increased to 2400 mg/day for the 
remaining 6 weeks unless clinical improvement occurred at a lower dose. MGH-HPS total scores 
decreased from a mean of 17.6 ± 4.64 at baseline to 10.4 ± 5.55 (95% CI and p<.001.)3 (Table 3) 
Table 3: Results of Double-blind NAC/Placebo Therapy in 50 TTM Subjects 
Variable Baseline Placebo 
Group (n=25)  
Baseline NAC 
Group (n=25) 
End Point 
Placebo Group 
(n=25) 
End Point NAC 
Group (n=25) 
P value CI 
MGH-HPS 
Total Score 
16.7 (5.28)a  17.6 (4.64)a 16.0 (4.90)a 10.4 (5.55)a <.001 95% 
a Value, mean (SD) 
Of the 25 subjects assigned to NAC, 44% (n=11) had a 50% or greater reduction on the 
MGH-HPS compared to 0% of those assigned to placebo (95% CI, p<.001). 3 NAC therapy in 
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TTM subjects demonstrates an experimental event rate (EER) of 44% and a control event rate 
(CER) of 0. The absolute risk reduction (ARR) is calculated at 44% and the number needed to 
treat (NNT) a TTM patient effectively with NAC is 2. (Table 2) 
Demographic features including but not limited to age, gender, age at TTM onset, and 
TTM severity did not cause statistically significant differences in treatment response among 
subjects.3 
Evaluations of blood pressure, heart rate and weight were recorded at each visit. Adverse 
effects included nausea, diarrhea and cough, experienced only in the placebo group.3 (Table 4) 
Table 4: Patients with TTM Reporting Adverse Effects 
Adverse Drug Event Placebo Group (n=25) NAC Group (n=25) P value 
Nausea 1 (4%) 0 >.99 
Diarrhea 2 (8%) 0 0.49 
Cough 1(4%) 0 >.99 
 
In the Grant, Kim et al. study, 27 pathological gambling subjects were included in the ITT 
analysis. Of these, 23 (85.2%) were able to keep to the study schedule and complete the study. 
Data were presented as dichotomous and were analyzed with the last observation carried forward 
in the ITT population. The study included an open-label trial followed by a double-blind RCT.4 
In the 8-week open-label component, PG subjects were seen weekly for weeks 1-4, then 
biweekly for weeks 4-8. Subjects were started on 600 mg/day of unblinded NAC for 2 weeks. 
NAC was increased to 1200 mg/day for the next 2 weeks, then to 1800 mg/day for the remainder 
of the study. Doses were not increased if clinical improvement was observed at a lower dose.4 
PG-YBOCS scores decreased from a mean of 20.3 ± 4.08 at baseline to 11.8 ± 9.81 after 8 
weeks [t(50)= 4.17 and p<.001].(Table 5) Responders were defined as those with a ≥30% 
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decrease in PG-YBOCS total score. Considering only those who completed the study, (n=23) ,16 
(69.6%) were responders on the PG-YBOCS at the end of the open-label phase.4 
Table 5: Results of Open-Label N-Acetylcysteine Treatment in 27 PG Subjects 
Measure Baseline Week 8 End Point Paired t test p 
PG-YBOCS Total 20.3 ± 4.08a 11.8± 9.81a 4.17 <.001 
a Value, mean (SD) 
Of the 16 subjects who responded to NAC, 13 continued with the 6-week double-blind 
phase. Three subjects chose not to assume the risk of loss of improvement in gambling 
symptoms. Six of the 13 subjects were randomized to the NAC dose at which they completed the 
open-label phase and 7 were randomized to an identical amount of placebo. At the end of the 
double-blind phase, 5 out of 6 subjects (83.3%) assigned to NAC still met responder criteria, 
compared to 2 out of 7 subjects (28.6%) assigned to placebo.(Figure 1) NAC also maintained 
improvement on the primary outcome measure, the PG-YBOCS Total Score (Table 6). 4 
“Figure 1. Percentage of subjects meeting responder criteria each week of the double-blind 
discontinuation phase. a” 
 
 a This figure and its title comes directly from Grant, Kim et al.4 
Table 6: Results of 13 PG Subjects Randomized to NAC or Placebo for 6 Weeks 
Outcome Measure Mean Rank Z Score p 
PG-YBOCS Total Score    
Placebo 10.6 -1.67 0.095 
Active 7.2   
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          NAC supplementation in individuals with PG demonstrates an EER of 83.3% and a CER 
of 28.6%.4 This study demonstrates a RRR of 190% and an ARR of 54.7% for pathological 
gamblers taking NAC. The number needed to treat (NNT) a pathological gambler with NAC 
based on these results is two (Table 2). The mean effective daily dose of NAC was 1476.9 ± 
311.3 mg. The only adverse event was mild flatulence, reported by two subjects.4  
In the case study by Odlaug et al., five subjects were enrolled and underwent structured 
clinical interviews. 5 Two of the five subjects (40%) did not respond to treatment with NAC. 5 
Results of this study include those of the three individuals who responded.  
The first subject reported cessation of urges to engage in nail biting and hair pulling for 3 
months on1800 mg/day of NAC. The only side effect reported was mild flatulence during the 
first 2 weeks. The second subject achieved abstinence from TTM symptoms after 5 months of 
2400 mg/day NAC. She reported the cessation of hair pulling and associated urges and was able 
to stop wearing her wig. She reported no side effects. The third subject reported 4 months of 
abstinence from skin picking with only occasional mild urges on 1800 mg/day. Reports of her 
side effects were not included in the study. 5 (Table 7) 
Table 7: Results of NAC in Individuals with Pathological Grooming Disorders 
Subject Diagnosis Symptoms Intervention Result Adverse 
effects 
28 y.o. 
white male 
Nail biting x 
22 yrs and 
TTM x16 yrs 
Daily biting 2-3 
hrs/d; Hair pulling 
30 min/d; 
Significant social 
impairment 
NAC 600 mg/d x 2 
wks increased to 
1200 mg/d, then to 
1800 mg/d 
Cessation of 
urges/thoughts to 
engage in compulsive 
behavior x 3 mos.  
Mild 
flatulence 
x 2 weeks 
40 y.o. 
white 
female 
TTM x 36 
years 
Daily hair pulling 
from head and pubic 
area; intense shame 
+ embarrassment  
NAC 600 mg/d  
increased to 1200 
mg/d, then to 1800 
mg/d, finally to 2400 
mg/d 
Cessation of pulling + 
urges; Ability to stop 
wearing wig; 
Abstinence at 5 mos.  
None 
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Subject Diagnosis Symptoms Intervention Result Adverse 
effects 
52 y.o. 
African 
American 
female 
Skin picking 
x 37 years 
Daily uncontrollable  
picking of skin on 
arms + legs; 
Frequent infections  
NAC 600 mg/d 
increased to 1200 
mg/d, then to 1800 
mg/d 
Absence of picking 
behavior w/ only 
occasional mild urges 
x 4 mos. 
Not 
reported 
 
Discussion: 
 Grant, Odlaug et al.’s study shows improvement on the primary outcome measure in the 
experimental group with effects seen within 9 weeks of treatment initiation.3  
 Grant, Kim et al.’s study shows improvement of PG symptoms in the majority of subjects 
taking NAC. This study, however, has some limitations. Findings were based on a small 
population and only NAC responders were included in the second trial phase, possibly leading to 
exaggeration of NAC’s effects relative to placebo. 4Also, subjects with depression were taking 
medications in addition to the NAC, possibly affecting its efficacy. 4 An interesting finding in 
this study was that the few subjects taking psychotropic medications did not respond to NAC. 4  
 Odlaug et al.’s study, while informative, consisted of a particularly small population size 
and only studied those who saw improvement with NAC. Controlled studies to investigate the 
same interventions applied in this study are needed to confirm the findings. 
 The above trials were limited by the fact that the optimal effective dose of NAC has yet 
to be established.9 Subjects in the above trials who did not respond to NAC or who responded 
minimally may have had better outcomes with higher doses. Overdose of NAC, however, can 
lead to seizures and vigilance with its administration necessary 9. Secondly, the long-term effects 
of NAC can not be assessed from these studies, which designed brief treatment periods in a 
population of subjects with a chronic, often lifelong disorder.4  Longer term treatment may have 
shown higher levels of response. Lastly, these studies did not examine NAC treatment in 
Diamond, NAC and Impulse Control Disorders, 11 
 
conjunction with CBT, which has proven to be beneficial in the treatment of ICD’s.3 The 
potential synergistic effects of CBT with NAC supplementation has yet to be investigated.  
Conclusion: 
 The studies reviewed provide inconclusive evidence regarding the use of NAC in the 
treatment of impulse control disorders. NAC appears to be a promising alternative, but given the 
small population sizes and short-term use in the studies reviewed, further research is required. 
ICD’s may require more individualized treatment approaches based on the severity and type of  
ICD, presence of co-morbid psychiatric disease, and individual treatment response. Future 
studies focused on NAC treatment in conjunction with other treatments and in tailored amounts 
would provide more insight. NAC is generally well-tolerated with minimal adverse effects, but 
there is currently no evidence for adverse outcomes with long-term use. 9 Long-term effects must 
be understood before NAC can be used in the clinical setting.  
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